Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(29%)
Results Posted
100%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Active, not recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

completed343%
terminated114%
withdrawn114%
active_not_recruiting229%

Recent Activity

2 active trials
Showing 5 of 7
completedphase_2

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

NCT05583552
active_not_recruitingphase_1

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT05371964
active_not_recruitingphase_2

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
withdrawnphase_2

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT02011126
terminatedphase_2

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

NCT01836549
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05583552Phase 2

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Completed
NCT05371964Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Active Not Recruiting
NCT02598661Phase 2

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Active Not Recruiting
NCT02011126Phase 2

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Withdrawn
NCT01836549Phase 2

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Terminated
NCT01256762Phase 2

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed
NCT01273090Phase 1

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7